

GB107, Gene therapy for ischemic limb disease via new expression vector and PT1 technology

G&P Bioscience



CARDIOVASCULAR	Candidate
Product Type	Plasmid DNA (the highest HGF expression) + PT1 (drug delivery system)
Indication	Ischemic limb disease(Peripheral arterial disease, Diabetic peripheral neuropathy)
Target	Hepatocyte growth factor (HGF)
MoA(Mechanism of Action)	Promoting angiogenesis and collateral vessels via HGF expression in ischemic regions
Competitiveness	As compared with naked DNA (Collatogene or Engensis) <ul style="list-style-type: none"> • HGF expression over 10 times in vivo • Increased angiogenesis in rabbit PAD model • Improved pain and movement as clinical signs in rat DPN model
Development Stage	Candidate
Route of Administration	Intramuscular injection